Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™
AQST(NASDAQ:AQST) WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that an advisory committee meeting is not required for Anaphylm™ (dibutepinephrine) Sublingual Film. The Prescription Drug User Fee Act (PDUFA) target action date for Anaphylm remains January 31, 2026.
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
AQSTWARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in three upcoming investor conferences in September 2025 as follows:
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
AQSTWARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten offering of 21,250,000 shares of its common stock at an offering price of $4.00 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be $85 million. The Company intends to use the net proceeds received from the offering, together with the Company’s existing cash and cash equivalents, primarily to advance the launch and commercialization of Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, assuming United States Food and Drug Administration (FDA) approval, and fo
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
AQSTWARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a $75 million strategic funding agreement with funds managed by RTW Investments, LP (“RTW”), subject to United States Food and Drug Administration (FDA) approval of Anaphylm™ (epinephrine) Sublingual Film and other conditions.
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
AQSTWARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update.
Oppenheimer Assumes Aquestive Therapeutics at Outperform, Lowers Price Target of $7
AQSTHC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
AQSTAquestive Therapeutics Lowers FY2025 Sales Guidance from $47.00M-$56.00M to $44.00M-$50.00M vs $49.60M Est
AQSTAquestive Therapeutics Q1 EPS $(0.24) Misses $(0.17) Estimate, Sales $8.72M Miss $12.23M Estimate
AQSTUncovering Potential: Aquestive Therapeutics's Earnings Preview
AQSTHC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
AQSTAquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data
AQSTAquestive's Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025.
Aquestive Therapeutics Announced Topline Results From Its Pediatric Study For Anaphylm (Epinephrine) Sublingual Film In Patients Aged 7 To 17 And Weighing Over 30kgs With A Personal History Of Allergic Reactions, FDA Application Acceptance Expected In Q2
AQSTHC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
AQSTLake Street Maintains Buy on Aquestive Therapeutics, Lowers Price Target to $8
AQSTAquestive Therapeutics Sees FY2025 Total revenue $47.000M-$56.000M vs $52.95M Est
AQSTAquestive Therapeutics Q4 GAAP EPS $(0.19) Misses $(0.14) Estimate, Sales $11.87M Miss $13.08M Estimate
AQSTAquestive Therapeutics Outlines 2025 Goals, Including Anaphylm Launch and AQST-108 Phase 2a Trial
AQSTHC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
AQSTAquestive Therapeutics Secures FDA Orphan Drug Exclusivity For Libervant Buccal Film In Pediatric Seizure Clusters Ages 2 To 5, Highlighting Major Care Advancement With Buccal Administration Over Rectal Route
AQSTAquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity For Libervant Buccal Film In Pediatric Patients With Seizure Clusters Ages 2-5
AQSTHC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
AQSTAquestive Therapeutics Q3 EPS $(0.13), Inline, Sales $13.54M Beat $12.68M Estimate
AQSTAquestive Therapeutics Affirms FY2024 Sales Guidance to $57.00M-60.00M VS Est. 58.01M
AQSTEarnings Outlook For Aquestive Therapeutics
AQSTAquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement.
Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.41.
